Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 117-126

  Huang, Ching Ting ^a   Chang, Ming Cheng ^a   Chen, Yu Li ^b   Chen, Tsung Ching ^a   Chen, Chi An ^a   Cheng, Wen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Antigen presenting; Dendritic cells; IGF1R; Insulin like growth factor; NVP AEW541

Indexed keywords

INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL ASSAY; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

MUS;

EID: 84964296335     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.007     Document Type: Article

References (45)

1. Garfinkel L. Overweight and cancer. Ann. Intern. Med 1985, 103:1034-1036.
2. Tania M., Khan M.A., Song Y. Association of lipid metabolism with ovarian cancer. Curr. Oncol 2010, 17:6-11.
3. Hursting S.D., Lashinger L.M., Colbert L.H., Rogers C.J., Wheatley K.W., Nunez N.P., et al. Energy balance and carcinogenesis: underlying pathways and targets for intervention. Curr. Cancer Drug Targets 2007, 7:484-491.
4. Thompson H.J., Zhu Z., Jiang W. Weight control and breast cancer prevention: are the effects of reduced energy intake equivalent to those of increased energy expenditure?. J. Nutr 2004, 134:3407S-3411S.
5. Hursting S.D., Lashinger L.M., Wheatley K.W., Rogers C.J., Colbert L.H., Nunez N.P., et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link. Best Pract. Res. Clin. Endocrinol. Metab 2008, 22:659-669.
6. Surmacz E. Obesity hormone leptin: a new target in breast cancer?. Breast Cancer Res 2007, 9:301.
7. Singh P., Dai B., Yallampalli U., Lu X., Schroy P.C. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 1996, 137:1764-1774.
8. Fenton J.I., Hord N.G., Lavigne J.A., Perkins S.N., Hursting S.D. Leptin, insulin-like growth factor-1, and insulin-like growth factor-2 are mitogens in ApcMin/+but not Apc+/+ colonic epithelial cell lines. Cancer Epidemiol. Biomarkers Prev 2005, 14:1646-1652.
9. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev 2007, 28:20-47.
10. Rodon J., DeSantos V., Ferry R.J., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther 2008, 7:2575-2588.
11. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov 2007, 6:821-833.
12. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
13. Huang X., Venet F., Chung C.S., Lomas-Neira J., Ayala A. Changes in dendritic cell function in the immune response to sepsis. Cell- & tissue-based therapy. Expert Opin. Biol. Ther 2007, 7:929-938.
14. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol 2000, 18:767-811.
15. Abboud S.L., Bethel C.R., Aron D.C. Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J. Clin. Invest 1991, 88:470-475.
16. Stuart C.A., Meehan R.T., Neale L.S., Cintron N.M., Furlanetto R.W. Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J. Clin. Endocrinol. Metab 1991, 72:1117-1122.
17. Kooijman R., Willems M., De Haas C.J., Rijkers G.T., Schuurmans A.L., Van Buul-Offers S.C., et al. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 1992, 131:2244-2250.
18. Badolato R., Bond H.M., Valerio G., Petrella A., Morrone G., Waters M.J., et al. Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J. Clin. Endocrinol. Metab 1994, 79:984-990.
19. Geenen V., Achour I., Robert F., Vandersmissen E., Sodoyez J.C., Defresne M.P., et al. Evidence that insulin-like growth factor 2 (IGF2) is the dominant thymic peptide of the insulin superfamily. Thymus 1993, 21:115-127.
20. Sukhanov S., Higashi Y., Shai S.Y., Vaughn C., Mohler J., Li Y., et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol 2007, 27:2684-2690.
21. Park S.E., Dantzer R., Kelley K.W., McCusker R.H. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. J. Neuroinflammation 2011, 8:12.
22. Cheng W.F., Hung C.F., Chai C.Y., Chen C.A., Lee C.N., Su Y.N., et al. Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 2007, 110:420-431.
23. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-26.
24. Wang T.L., Ling M., Shih I.M., Pham T., Pai S.I., Lu Z., et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000, 7:726-733.
25. Gosland M.P., Lum B.L., Sikic B.I. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res 1989, 49:6901-6905.
26. Chang M.C., Lee C.N., Chen Y.L., Chiang Y.C., Sun W.Z., Hu Y.H., et al. Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects. Clin. Sci. (Lond.) 2012, 123:347-360.
27. Garcia-Echeverria C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004, 5:231-239.
28. Vabulas R.M., Pircher H., Lipford G.B., Hacker H., Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J. Immunol 2000, 164:2372-2378.
29. Rowlands M.A., Holly J.M., Hamdy F., Phillips J., Goodwin L., Marsden G., et al. Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 2012, 23:347-354.
30. Iizuka N., Oka M., Tamesa T., Hamamoto Y., Yamada-Okabe H. Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma. Anticancer Res 2004, 24:4085-4089.
31. Zhan M., Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol. Histopathol 2004, 19:915-923.
32. Wilker E., Lu J., Rho O., Carbajal S., Beltran L., DiGiovanni J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Mol. Carcinog 2005, 44:137-145.
33. Liu E., Law H.K., Lau Y.L. Insulin-like growth factor I promotes maturation and inhibits apoptosis of immature cord blood monocyte-derived dendritic cells through MEK and PI 3-kinase pathways. Pediatr. Res 2003, 54:919-925.
34. Matte I., Lane D., Laplante C., Rancourt C., Piche A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am. J. Cancer Res 2012, 2:566-580.
35. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med 2006, 203:871-881.
36. Giuntoli R.L., Webb T.J., Zoso A., Rogers O., Diaz-Montes T.P., Bristow R.E., et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009, 29:2875-2884.
37. Ullrich E., Menard C., Flament C., Terme M., Mignot G., Bonmort M., et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008, 19:79-92.
38. Fujii S., Takayama T., Asakura M., Aki K., Fujimoto K., Shimizu K. Dendritic cell-based cancer immunotherapies. Arch. Immunol. Ther. Exp. (Warsz) 2009, 57:189-198.
39. Ioannou N., Seddon A.M., Dalgleish A., Mackintosh D., Modjtahedi H. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013, 13:41.
40. Cortot A.B., Repellin C.E., Shimamura T., Capelletti M., Zejnullahu K., Ercan D., et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013, 73:834-843.
41. Pavlicek A., Lira M.E., Lee N.V., Ching K.A., Ye J., Cao J., et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol. Cancer Ther 2013, 12:2929-2939.
42. Wang Y., Adachi Y., Imsumran A., Yamamoto H., Piao W., Li H., et al. Targeting for insulin-like growth factor-I receptor with short hairpin RNA for human digestive/gastrointestinal cancers. J. Gastroenterol 2010, 45:159-170.
43. Dziadziuszko R., Camidge D.R., Hirsch F.R. The insulin-like growth factor pathway in lung cancer. J. Thorac. Oncol 2008, 3:815-818.
44. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P.L., Maurici D., et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996, 56:4570-4574.
45. Tolcher A.W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C.C., Rodon J., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J. Clin. Oncol 2009, 27:5800-5807.